About Cardiff Oncology Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://cardiffoncology.com/
Frequently Asked Questions
What is the 52-week range for CRDF?
The 52-week high is $3.31 and the 52-week low is $0.7566.
What is the P/E ratio for CRDF?
The P/E ratio data is currently unavailable.
What is the dividend yield for CRDF?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -103.08%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7884.06%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.17.
Analyst Recommendation Trends
Wall Street analyst consensus for CRDF over the last few months:
Latest CRDF News
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.
Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow
2026-09-10. The following slide deck was published by Cardiff Oncology, Inc.
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-14 | Mohindru Mani | +34,364 | - | - |
| 2026-07-14 | Mohindru Mani | +34,364 | $1.455 | $50,000 |
| 2026-07-14 | PACE GARY W | +687,285 | - | - |
| 2026-07-14 | PACE GARY W | +687,285 | $1.455 | $1,000,000 |
| 2026-06-18 | Mohindru Mani | +24,703 | $1.21 | $29,891 |
| 2026-06-18 | PACE GARY W | +30,000 | $1.22 | $36,600 |
| 2026-06-11 | White Lale | +40,565 | - | - |
| 2026-06-11 | TANNENBAUM RENEE P | +40,565 | - | - |
| 2026-06-11 | Markin Rodney S | +40,565 | - | - |
| 2026-06-11 | Armitage James O | +40,565 | - | - |
| 2026-06-11 | PACE GARY W | +40,565 | - | - |
| 2026-04-27 | Aggarwal Ajay | +400,000 | - | - |
| 2026-04-14 | Smeal Tod | +300,000 | - | - |
| 2026-04-06 | Muntner Joshua B | +486,650 | - | - |
| 2026-04-06 | Muntner Joshua B | +486,650 | - | - |
| 2026-03-31 | Mohindru Mani | +600,000 | - | - |
| 2026-02-17 | Mohindru Mani | +200,000 | - | - |
| 2026-02-13 | Lindsay Brigitte Ute | +200,000 | - | - |